INTRODUCTION

Na\textsuperscript{+}-K\textsuperscript{+}-ATPase, discovered by Skou,\textsuperscript{1} is one of the most crucial Adenosine-5\textsuperscript{'}-Triphosphate (ATP)-powered P-type ion transporters.\textsuperscript{2-4} It is essential for normal structure and function of all cell membranes.\textsuperscript{2-4} Its primary functions include maintenance ion gradient across membranes\textsuperscript{2-4} and uptake and release of neurotransmitters.\textsuperscript{5-7} Therefore, Na\textsuperscript{+}-K\textsuperscript{+}-ATPase plays a crucial role in ion homeostasis and cellular excitability.\textsuperscript{2-4} Dysfunction of Na\textsuperscript{+}-K\textsuperscript{+}-ATPase may lead to many types of central nervous system (CNS) disorders, including epilepsy.\textsuperscript{8-11} Epilepsy is a common neurological disorder characterized by recurrent spontaneous seizures,\textsuperscript{12} caused by the highly synchronized firing of neurons with hyperexcitability.\textsuperscript{13} It affects about 70 million population around the world.\textsuperscript{14} Unfortunately, about one-third of epileptic patients remain drug-resistant,\textsuperscript{15} leading to a situation that needs a more effective drug target. An increasing number of studies unveiled a significant role of Na\textsuperscript{+}-K\textsuperscript{+}-ATPase in epilepsy.\textsuperscript{1-2} Notably, mutation of genes encoding Na\textsuperscript{+}-K\textsuperscript{+}-ATPase leads to epilepsy as part of its phenotype. In rodent models of epilepsy, the activity of Na\textsuperscript{+}-K\textsuperscript{+}-ATPase was reported to change as well. Pharmacological inhibition of Na\textsuperscript{+}-K\textsuperscript{+}-ATPase will cause epileptic seizure in rodents as well. Na\textsuperscript{+}-K\textsuperscript{+}-ATPase activating antibody, by contrast, was reported to have a protective effect on epilepsy. However, discordant results are not uncommon, probably due to differences in etiologies, testing timing, features of various epilepsy models, etc. Hence, in this review, we briefly summarize structure and physiological function of Na\textsuperscript{+}-K\textsuperscript{+}-ATPase in the CNS. Then we aim to summarize and evaluate current understandings of Na\textsuperscript{+}-K\textsuperscript{+}-ATPase in the epileptic brain and also therapeutic strategies associated with the
Na+K+-ATPase. We also provide perspectives on some possible research directions to address the role of Na+K+-ATPase in epilepsy.

2 | STRUCTURE AND FUNCTION OF Na+-K+-ATPase IN THE CNS

Na+-K+-ATPase is composed of three subunits, including α, β, and FXYD phenylalanine- X-tyrosine-aspartate amino acid sequence. One molecule of Na+-K+-ATPase contains three molecules of α subunits and two molecules of β subunits.16,17 The α subunit consists of four kinds of different subtypes (α1–α4), with the first three being expressed in the CNS. The α1 subtype is expressed in neurons, and glial cells, α2 mainly in astrocytes,18 and α3 in neurons.19,20 The β subunits are expressed in neurons, astrocytes, and oligodendrocytes. The distribution of each subunit is summarized in Table 1.

The α subunit is the catalytic subunit, containing three envelope domains and ten transmembrane helices. Exporting or importing ions is accomplished by changing two conformational states, E1 and E2. E1 faces the cytoplasm, which has a high affinity for sodium ions. E2 faces extracellular space, with a low affinity for sodium ions but a high affinity for potassium ions.2 The function of Na+-K+-ATPase is primarily related to the α subunit, which alternates between E1/ E2 and phosphorylated E1 (E1-p)/phosphorylated E2 (E2-p). By conformational changes of phosphorylation and dephosphorylation, the affinity to sodium and potassium ions also changes.21 When the α subunit binds sodium ions through the E1 state, which has a high affinity to sodium ions, ATP is going to be hydrolyzed. Once one molecule of ATP is hydrolyzed, three sodium ions will be transported to extracellular compartment while two potassium ions to the intracellular compartment,20,22 which further raises the resting membrane potential.

The β subunit mainly assists the newly synthesized α subunit with folding, targeting, and correct insertion into the cell membrane,23 thereby stabilizing the structure and regulating the activity of the α subunit.24 The β subunit includes three isoforms (β1–β3)25,26 and is vital in the α subunit to the plasma membrane and functions as an intercellular adhesion protein.27 Three of the seven members of the FXYD family were found to modulate the affinity of the α subunit for sodium and potassium ions.28

3 | Na+-K+-ATPase AND SEIZURES/ EPILEPSY: EVIDENCE FROM BENCH AND BEDSIDE

3.1 | Na+-K+-ATPase gene mutation leads to epilepsy

Current evidence based on patients with Na+-K+-ATPase gene mutation found epilepsy to be a frequent occurrence as phenotypes. In particular, all reported cases with ATPase genetic mutation fall into the sequences encoding the α subunit, with ATP1A1, ATP1A2 and ATP1A3 corresponding to the four subtypes of α subunit (Table 2).

3.1.1 | ATP1A1

Schlingmann et al.29 reported that heterozygous de novo mutations in ATP1A1 were found in children diagnosed with hypomagnesemia and epilepsy. These children developed symptoms of convulsions and hypomagnesemia in the infant period from 6 days to 6 months old. All children were treated with antiepileptic drugs and intravenous magnesium. However, seizures remained after a follow-up of about five years, with some even having status epilepticus (SE), indicating the refractoriness of their epilepsy. Apart from that, some of them also have severe intellectual disabilities. Lin et al.30 reported a clinical case of a boy aged 2 years and 10 months with a de novo ATP1A1 variant. He had severe developmental delay, developed epileptic seizures five months after birth, and later switched into generalized tonic-clonic seizures (GTCS).

3.1.2 | ATP1A2

Mutations in the ATP1A2 gene generally occur in familial hemiplegic migraine (FHM, familial hemiplegic migraine). About 6% of FHM patients have epilepsy and epileptic symptoms typically occur in

| Subunit | Function | Subtype | Distribution |
|---------|----------|---------|--------------|
| α       | Catalytic subunit: Ion transportation | α1 | Neurons and glial cells |
|         |          | α2 | Astrocytes and oligodendrocytes |
|         |          | α3 | Neurons |
| β       | Assists the newly synthesized α subunit in folding, targeting, and inserting cell membrane correctly | β1 | Neurons |
|         |          | β2 | Astrocytes |
|         |          | β3 | Oligodendrocytes |
| FXYD    | Modulates the affinity of α subunit for sodium and potassium ions | FXYD1 | Neurons and astrocytes |
|         |          | FXYD7 | Neurons and astrocytes |
adolescence. The cases of patient with mutation in ATP1A2 were reported to be associated with FHM and benign familial infantile convulsions. Moreover, FHM2 is a Mendelian model disease for spreading depolarization, and Clemens Reiffurth et al. showed only α2 heterozygous mice displayed higher spreading depolarization susceptibility, indicating the α2 subunit is crucial in this disease. In addition, homozygous truncating variants of ATP1A2 would cause a novel lethal recognizable polymicrogyria syndrome. Polymicrogyria is responsible for a wide range of neurological symptoms, including epilepsy. The mechanism under epileptogenicity of polymicrogyria remains unknown. However, unilateral multilobar polymicrogyria is often related to an age-related syndrome of epilepsy.

### 3.1.3 ATP1A3

Mutations in ATP1A3 are generally believed to be related to alternating hemiplegia in childhood. Those patients were reported to have concomitant epilepsy (pediatric case of catastrophic early life epilepsy), especially in those with mutations in p.Glu815Lys, p.Gly358Val, and p.Ile363Asn of ATP1A3. In addition, these mutations manifested as a decrease in the activity of the α3 subunit in vitro, which is the basis for these diseases. Further, Clapcote et al. also presented a mouse model for epilepsy caused by mutation of the Na+-K+-ATPase α3-isofrom, which show impairments in the sodium pump and hyperexcitability in the CNS.

Together, in clinical research, mutations in Na+-K+-ATPase are closely related to epilepsy. ATP1A1 codes for the α1 subunit of Na+-K+-ATPase, which is responsible for maintaining the membrane potential of neurons. A primary disease that is relevant to ATP1A1 mutation is hypomagnesemia and epilepsy. ATP1A2 gene corresponds with the α2 subunit of Na+-K+-ATPase, which is crucial for restoring membrane potential in astrocytes. ATP1A2 mutation is generally associated with familial hemiplegic migraine and polymicrogyria in the brain. The α3 subunit of Na+-K+-ATPase is encoded by ATP1A3, which is vital for maintaining ionic homeostasis in neurons and responsible for several brain diseases such as alternating hemiplegia in childhood. They all have epileptic symptoms. Previous studies have mainly focused on the clinical spectrum of patients with variants in the ATPase gene. However, effective treatment is still lacking. Targeted interventions using genetic manipulations are promising strategies for treating such diseases, which merit further investigations.

### 3.2 Na+-K+-ATPase in an animal model

#### 3.2.1 Change of Na+-K+-ATPase activity after epileptiform activity

A large number of studies indicated that Na+-K+-ATPase activity decreases in epilepsy. In epileptic seizures, abnormal activity of Na+-K+-ATPase can be found on the cell membrane of the cerebral cortex of animals and humans. The decrease of Na+-K+-ATPase activity was first reported by Hunt WA et al. in animal models of cobalt-induced epilepsy, where a significant reduction in enzyme activity was observed. In the human epileptic brain, the activity of Na+-K+-ATPase is significantly less in the epileptic human cortex than that in the nonepileptic cortex. The decrease of Na+-K+-ATPase activity was further corroborated in the model of audiogenic epilepsy.
pentylenetetrazole (PTZ)-induced seizures in rats, kainate-lesioned rats and in the pilocarpine model of temporal lobe epilepsy (especially one hour after SE). In the freeze lesion cat model, a decreased activity of Na+K+-ATPase was observed three weeks (chronic freeze lesion cat model) after the production of cold lesions. However, one report found that no significant differences were observed between epileptic mice and normal mice for Na+K+-ATPase activities in various brain regions, including the hippocampus, brain stem, or cerebellum, suggesting seizure susceptibility in epilepsy mice is not associated with differences in the activities of these Na+K+-ATPase activities.

Notably, 60 s after the production of cold lesions in the same model (acute freeze lesion cat model), Na+-K+-ATPase activity of the whole brain increases. In addition, in the pilocarpine model of epilepsy, during a chronic period, 120 days after pilocarpine-induced SE, the activity also increases. In TLE patient tissue, Na+K+-ATPase in surviving neurons is upregulated. It is speculated there is a compensatory change resulting from the increased total brain Na+.

As mentioned before, the activity of Na+K+-ATPase decreases in most situations. However, in some animal models, the activity increases. Moreover, Reime Kinjo57 and Fernandes52 reported discordant results, which may be due to the P16 rat used by Reime Kinjo E. From these conflicting data, it could be postulated that under different situations (different stages of epilepsy or different type of epilepsy models), the activity of Na+-K+-ATPase would vary. The various changes of Na+K+-ATPase activity in different animal models of seizure/epilepsy are summarized in Table 3.

### 3.2.2 Epileptic discharge after Na+K+-ATPase inhibition

Inhibition of Na+K+-ATPase will lead to epileptic seizure. Previous studies consistently employed ouabain or [3H]Ouabain as an inhibitor of Na+K+-ATPase. Ex vivo studies showed that 64.5% of ganglion neurons will depolarize after applying ouabain, along with a decrease in input resistance. Injection of ouabain into the cerebral cortex in vivo can also cause epileptic symptoms, and the symptoms will last for several hours. It is postulated that the Na+-Ca2+ exchange is strengthened after Na+K+-ATPase inhibition. This causes the intracellular Ca2+ to increase and leads to an increase in cellular excitability. However, there is currently a lack of specific inhibitors for the different subunit of Na+K+-ATPase, which lead to some unspecified outcome in studies using ouabain.

Using heterozygous knock-out mice, we could know that deficiency of the α2 isoform of Na+K+-ATPase increases spreading depolarization susceptibility in acute brain slices when exposed to high K+. Moreover, spreading depolarization has been proposed as a risk factor for the development of epilepsy.

### 3.2.3 Protective effects in epilepsy after applying Na+K+-ATPase activating antibody

Some researchers use Na+K+-ATPase activating antibody DRRSAb to activate the ion pump. Freitas ML et al. incubated brain slices with DRRSAb and reported a subsequent glutamate release ex vivo. Furthermore, activation of Na+K+-ATPase using DRRSAb in vivo decreased seizure susceptibility in the pilocarpine model of epilepsy. Funck et al. also found that DRRSAb will increase hippocampal Na+K+-ATPase activity in mice and attenuate seizure susceptibility in post-SE animal models. These results showed that the intervention of Na+K+-ATPase would impact epilepsy.

### 4 Na+K+-ATPase MODULATES CELL EXCITABILITY IN THE EPILEPTIC BRAIN

In the resting state, the cell membrane is much more permeable to potassium than sodium. The equilibrium potential of potassium ions dominates the resting membrane potential. Therefore,
Na+-K+-ATPase, which determines the potassium gradients across cell membranes, is an essential factor in the maintenance of the resting membrane potential and the regulation of ion homeostasis. We could understand the mechanisms underlying ATPase and cellular excitability from the perspective of sodium and potassium ions homeostasis, respectively (Figure 1).

4.1 | Sodium-ion homeostasis related excitability

4.1.1 | Decreased GABA transportation

GABA is the main inhibitory neurotransmitter in the CNS. In particular, GAT3 (GABA transporters 3) is one of the transporters of GABA, which is specifically expressed in astrocytes. The activity of GAT3 depends on the sodium ion gradient. Therefore, Na+-K+-ATPase dysfunction will lead to abnormalities in GABA transportation, thereby increasing CNS excitability.

4.1.2 | Dual influence on glycine and its transporter Glyt1b

The dysfunction of Na+-K+-ATPase will cause an increase in intracellular Na+ level. The rise of Na+ concentration has a dual influence on the NMDA receptor co-agonist glycine and its transporter Glyt1b. It may increase NMDA receptor-mediated excitation at a low concentration. However, at a higher concentration it may also exert an inhibitory effect on glycine-mediated activation.

4.1.3 | Calcium ion influx

Na+-K+-ATPase dysfunction will cause the accumulation of intracellular sodium ions, which will induce the activation of voltage-gated calcium pumps and the reversion of intercellular Na+-Ca2+ exchanger, leading to the rapid accumulation of intercellular free calcium ions. The rapid influx of calcium depolarizes the cell membrane due to its divalent positive charge, and it can also mediate action potential firing and potential membrane oscillations.

4.2 | Potassium ion homeostasis related excitability

4.2.1 | Dysfunction of glutamate clearing

Glutamate is the main excitatory neurotransmitter whose transporter in the synapse depends on excitatory amino acid transporters (EAATs). When one molecule of glutamate is transported, one

![Figure 1](https://example.com/figure1.png)

**FIGURE 1** Potential mechanisms of Na+-K+-ATPase dysfunction contributed to epilepsy. The inhibition of Na+-K+-ATPase could cause the accumulation of intracellular sodium ions, which will further lead to (1) inhibition of inward transportation of GABA; (2) increased NMDA receptor-mediated excitation; (3) accumulation of intercellular free calcium ions through the reversion of intercellular Na+-Ca2+ exchanger. Furthermore, Na+-K+-ATPase dysfunction is also associated with a decrease in intracellular potassium ion homeostasis, resulting in (1) impaired glutamate clearance; (2) an increase in resting membrane potential. With these mechanisms, Na+-K+-ATPase is a major contributor to brain excitability in epileptic brains. NKA, Na+-K+-ATPase; GAT3, GABA transporters 3; NXC, Na+-Ca2+ exchanger; EAATs, Excitatory amino acid transporters.
potassium ion is exported, and three sodium ions and one molecule of hydrogen ion are imported. With Na+-K+-ATPase dysfunction, glutamate will have clearance impairment, thereby increasing CNS excitability. 

4.2.2 | Increased resting potential

When the activity of Na+-K+-ATPase is inhibited, the active transport between sodium and potassium ions cannot be completed, leading to the accumulation of potassium extracellularly. This will be followed by an increase of resting membrane potential, finally leading to an increase of cellular excitability.

4.3 | Increased extracellular ATP concentrations

ATP was first proposed as a neurotransmitter by Geoffrey Burnstock et al. in the CNS, ATP operates as a fast excitatory neurotransmitter. Some studies reported an increase in extracellular ATP concentration during seizures. With Na+-K+-ATPase dysfunction, the concentration of ATP will increase. The elevated concentration of ATP will further activate purinergic P2 receptors, leading to an exacerbation of seizures. Among the subtypes of P2 receptors, hippocampal P2X7 receptors were reported to have a selective increase in the intra-amygdala kainic acid mice, which further promotes the glutamate release. However, the specific mechanism underlying P2 receptors and seizures remains unclear.

Although Na+-K+-ATPase dysfunction can lead to hyperexcitability in many ways, the mechanism of Na+-K+-ATPase involved in the epileptic brain is still not fully understood. Furthermore, how Na+-K+-ATPase in different types of cells, like neurons or glia, contributes to overall excitability is unclear.

4.4 | Dysfunction of injury-related autophagy

Brain injury is one of the most frequent causes of epilepsy. Brain injury is related to autophagy through Na+-K+-ATPase. The interaction between Na+-K+-ATPase and autophagy protein Beclin 1 increases when brain have an injury, including ischemia. Moreover, Na+-K+-ATPase dependent autophagy can produce a protective effect on brain injury. Interestingly, recent studies demonstrated that autophagy also has a close relationship with epilepsy. The abnormal activation of the mTOR pathway, which would impair autophagy, could cause various epilepsy syndromes. Specifically, conditional deletion of Atg7, an essential regulator of autophagy, in mouse forebrain neurons is sufficient to promote development of spontaneous seizures. The mechanism of which is due to disinhibition of mTOR pathway. In addition, balloon cells in the brains of focal cortical dysplasia (FCD) type IIb patients, a common type of epilepsy, exhibit an increase of autophagy-related proteins, which indicates autophagy is impaired in FCD. Inhibiting mTOR could reverse this phenomenon. Therefore, a prospective mechanism may exist in the role of Na+-K+-ATPase in epilepsy through the regulation of autophagy, which is worth exploring in the future.

5 | CONCLUSION AND PROSPECT

Na+-K+-ATPase is an ATP-driven ion transporter pivotal for physiological structure and function of cell activity. It is closely related to cellular excitability, which indicates the vital role of Na+-K+-ATPase in epilepsy. The presence of epileptic symptoms in numerous neurological diseases caused by the mutation of Na+-K+ ATPase subunits highly suggested the cause-and-effect relationship between Na+-K+ ATPase and epilepsy. Furthermore, a substantial change in the activity of Na+-K+-ATPase was observed in different epilepsy/seizure animal models, although discordant results among studies exits. Pharmacological inhibition of Na+-K+-ATPase in rodents will lead to cellular hyperexcitability and seizures. We further highlight the potential mechanisms underlying the role of Na+-K+-ATPase dysfunction and cellular hyperexcitability, which is mainly mediated by the change in sodium and potassium ion homeostasis.

However, several questions remain unknown, which mainly revolve around the impact of Na+-K+-ATPase on epilepsy and its clinical translational significance.

1. The detailed change of Na+-K+-ATPase in epilepsy, including the protein level and subunit alterations, remains elusive. Through investigating the protein level, the direct reason why the activity of Na+-K+-ATPase has changed might be explained. Furthermore, the role of each subunit of Na+-K+-ATPase in epilepsy must be further clarified. Each subunit of Na+-K+-ATPase exists in different cell types. Understanding changes in specific subunits will better address the cell-specific role of Na+-K+-ATPase in epilepsy. This can assist us in finding new drug targets and explore a series of recent drug structures.

2. In different types and phases of epileptogenesis, the role of Na+-K+-ATPase may vary. In clinical, genetic diseases with mutations in the gene encoding Na+-K+-ATPase can have different types of epilepsy manifestations. The pathophysiological contribution of Na+-K+-ATPase in those patients remains to be further investigated. Moreover, in other types of epilepsy, including TLE with hippocampal sclerosis and FCD, the role of Na+-K+-ATPase remains uninvestigated as well. Whether Na+-K+-ATPase contributes to epileptic seizure in a common way or via various mechanism in different types of epilepsy needs to be investigated. Further, investigation of the function of Na+-K+-ATPase in different phases of epileptogenesis, including acute epileptogenic phase, latency period and chronic spontaneous seizure period, will be of great value in understanding its role in the development of epilepsy.

3. Currently, no one drug that specifically intervene Na+-K+-ATPase exists. With specific drugs, the function of Na+-K+-ATPase could
be evident. Moreover, it would have clinical transformational prospects if such specific drugs could be discovered.

4. The cell-specific role of Na⁺-K⁺-ATPase remains largely uninvestigated. The fact that each subunit of Na⁺-K⁺-ATPase predominates in different cell types might indicate distinct functions of subunits. Previous research failed to identify the cell-specific role of Na⁺-K⁺-ATPase in pathological states, including epilepsy. Combined with gene intervention with Cre-Loxp strategy or subunit-specific drug with structural virtual screening, the cell-specific functions of Na⁺-K⁺-ATPase would have paramount therapeutic implications not only for the treatment of epilepsy, but also other neurological diseases.

AUTHOR CONTRIBUTIONS
ZC and YW conceptualized the review. JYS and YZ conducted the systematic search and extracted the eligible studies. JYS drafted the review. ZC and YW conceptualized the review. JYS and YZ conducted the review. YW and YZ revised the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS
This project was supported by grants from the National Natural Science Foundation of China (81973298) and Natural Science Foundation of Zhejiang Province (LD22H310003).

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT
Not applicable.

ORCID
Zhong Chen https://orcid.org/0000-0003-4755-9357
Yi Wang https://orcid.org/0000-0002-1350-2961

REFERENCES
1. Skou JC. The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta. 1957;23(2):394-401.
2. Kanai R, Ogawa H, Vilsen B, Cornelius F, Toyoshima C. Crystal structure of a Na⁺-bound Na⁺,K⁺-ATPase preceding the E1P state. Nature. 2013;502(7470):201-206.
3. Kaplan JH. Biochemistry of Na,K-ATPase. Annu Rev Biochem. 2002;71:511-535.
4. Morth JP, Pedersen BP, Toustrup-Jensen MS, et al. Crystal structure of the sodium-potassium pump. Nature. 2007;450(7172):1043-1049.
5. Funck VR, Ribeiro LR, Pereira LM, et al. Contrasting effects of Na⁺, K⁺-ATPase activation on seizure activity in acute versus chronic models. Neuroscience. 2015;298:171-179.
6. Bublitz M, Poulsen H, Morth JP, Nissen P. In and out of the ion pumps: P-type ATPase structure revisited. Curr Opin Struct Biol. 2010;20(4):431-439.
7. Marquezan BP, Funck VR, Oliveira CV, et al. Pentyleneetetrazol-induced seizures are associated with Na⁺,K⁺-ATPase activity decrease and alpha subunit phosphorylation state in the mice cerebral cortex. Epilepsy Res. 2013;105(3):396–400.
8. Mahad DJ, Zibareva I, Campbell G, et al. Mitochondrial changes within axons in multiple sclerosis. Brain. 2009;132(5):1161-1174.
9. McKeon A, Ozelius LJ, Hardiman O, Greenway MJ, Pittcock SJ. Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-parkinsonism kindred. Mov. Disord. 2007;22(9):1325-1327.
10. Van Den Maagdenberg AM, Terwindt GM, Haan J, Frants RR, Ferrari MD. Genetics of headaches. Handb Clin Neurol. 2010;97:85-97.
11. Grisar T, Guillaume D, Delgado-Escueta AV. Contribution of Na⁺,K⁺-ATPase to focal epilepsy: a brief review. Epilepsy Res. 1992;12(2):141-149.
12. Schmidt D, Sillanpää M. Evidence-based review on the natural history of the epilepsies. Curr Opin Neurol. 2012;25(2):159-163.
13. Lan W, Liu X, Wu Z, et al. Activation of extrasynaptic GABA(A) receptors inhibits cytohazide-induced epileptiform activity in hippocampal CA1 neurons. Neurosci Bull. 2014;30(5):866-876.
14. Thijs RD, Surges R, O’Brien TJ, Sander JW. Epilepsy in adults. Lancet. 2019;393(10127):689-701.
15. Lösscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606-638.
16. Sweadner KJ. Isozymes of the Na⁺/K⁺-ATPase. Biochim Biophys Acta. 1989;988(2):185-220.
17. McGrail KM, Phillips JM, Sweadner KJ. Immunofluorescent localization of three Na,K-ATPase isoforms in the rat central nervous system: both neurons and glia can express more than one Na,K-ATPase. J Neurosci. 1991;11(2):381-391.
18. Krivoli I. Regulatory function of the Na,K-ATPase alpha2 isoform. Biofizika. 2012;57(5):771-788.
19. Dobretsov M, Stimers JR. Neuronal function and alpha3 isoform of the Na/K-ATPase. Front Biosci. 2005;10:2373-2396.
20. Shrivastava AN, Triller A, Melki R. Cell biology and dynamics of Neuronal Na⁺/(K⁺)+ATPase in health and diseases. Neuropharmacology. 2020;169:107461.
21. Morth JP, Poulsen H, Toustrup-Jensen MS, et al. The structure of the Na⁺,K⁺-ATPase and mapping of isoform differences and disease-related mutations. Philos Trans R Soc Lond B Biol Sci. 2009;364(1514):217-227.
22. Poulsen H, Khandelia H, Morth JP, et al. Neurological disease mutations compromise a C-terminal ion pathway in the Na⁺/(K⁺)+ATPase. Nature. 2010;467(7311):99-102.
23. Stahl WL. (Na⁺ + K⁺)-ATPase: function, structure, and conformations. Ann Neurol. 1984;16(5):121-127.
24. Cicirarelli S, Aperia A, Nissen P. How are ion pumps and agrin signaling integrated? Trends Biochem Sci. 2010;35(12):653-659.
25. Lee MS, Chait RM. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties. Proc Natl Acad Sci USA. 2001;98(17):9595-9600.
26. Geering K. The functional role of beta subunits in oligomeric P-type ATPases. J Bioenerg Biomembr. 2001;33(5):425-438.
27. Blanco G. Na,K-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation. Semin Nephrol. 2005;25(5):292-303.
28. Geering K. Functional roles of Na,K-ATPase subunits. Curr Opin Nephrol Hypertens. 2008;17(5):526-532.
29. Crawford G, Fuzesi M, Garty H, Karlish S, Geering K. Phospholemman (FXYD1) associates with Na,K-ATPase and regulates its transport properties. Proc Natl Acad Sci USA. 2002;99(17):11476-11481.
30. Schlingmann KP, Bandulik S, Mammen C, et al. Germline de novo mutations in ATP1A1 cause renal hypomagnesemia, refractory seizures, and intellectual disability. Am J Hum Genet. 2018;103(5):808-816.
31. Lin Z, Li J, Ji T, Wu Y, Gao K, Jiang Y. ATP1A1 de novo mutation-related disorders: clinical and genetic features. Trends Pediatr. 2021;9:657256.
33. Gallanti A, Tonelli A, Cardin V, Bussone G, Bresolin N, Bassi MT. A novel de novo nonsense mutation in ATP1A2 associated with sporadic hemiplegic migraine and epileptic seizures. J Neurosci. 2008;28(1-2):123-126.

34. Vetro A, Nielsen HN, Holm R, et al. ATP1A2- and ATP1A3-associated early profound epileptic encephalopathy and polydyslexia. Brain. 2012;137(8):2209-2222.

35. Biondo ED, Spontarelli K, Ababioh G, Méndez L, Artigas P. Diseases caused by mutations in the Na(+)/K(+) pump α1 gene ATP1A1. Am J Physiol Cell Physiol. 2021;321(2):C334-C340.

36. Clapcote SJ, Duffy S, Xie G, et al. Mutation I810N in the α3 Na(+)/K(+) ATPase α isoform deficiency results in distinct spreading depolarization phenotypes. J Cereb Blood Flow Metab. 2020;40(3):622-638.

37. Chatron N, Cabet S, Alich E, et al. A novel lethal recognizable polymicrogyria syndrome caused by ATP1A2 homozygous truncating variants. Ann Neurol. 2003;54(3):360-366.

38. Biondo ED, Spontarelli K, Ababioh G, Méndez L, Artigas P. Diseases caused by mutations in the Na(+)/K(+) pump α1 gene ATP1A1. Am J Physiol Cell Physiol. 2021;321(2):C334-C340.

39. Guerrini R, Genton P, Bureau M, et al. Multilobar polymicrogyria. J Physiol Cell Physiol. 2003;54(1):171-180.

40. vanmolkot KR, Kors EE, Hottenga JJ, et al. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. Epilepsia. 2015;56(3):422-430.

41. Ishihara N, Inagaki H, Miyake M, Kawamura Y, Yoshihaka T, Kurahashi H. A case of early onset life-threatening epilepsy associated with a novel ATP1A3 gene variant. Brain Dev. 2019;41(1):285-291.

42. Clapcote SJ, Duffy S, Xie G, et al. Mutation I810N in the α3 isoform of Na(+)/K(+) ATPase causes impairments in the sodium pump and hypertrophy in the CNS. Proc Natl Acad Sci USA. 2009;106(33):14085-14090.

43. de Lores Arnaiz GR, Ordiere MG. Brain Na(+), K(+) ATPase activity in aging and disease. Int J Biochem Sci. 2014;10(2):85-102.

44. Holm TH, Lykke-Hartmann K. Insights into the pathology of the α3 Na+/K+ ATPase ion pump in neurological disorders; lessons from animal models. Front Physiol. 2016;7:209.

45. Grisar T. Gliarial and neuronal Na(+)+K+ pump in epileptic syndromes; lessons from animal models. Front Physiol. 1997;36(1):69-72.

46. Nagy AK, Houser CR, Delgado-Escueta AV. Synaptosomal ATPase activities in temporal cortex and hippocampal formation of humans with focal epilepsy. Brain Res. 1990;529(1-2):192-201.

47. Oner P, Oztas B, Kocak H. Brain cortex Na(+)+K+ ATPase activity in streptozotocin-diabetic and pentylentetrazol-epileptic rats. PharmacoL Res. 1997;36(1):69-72.

48. Hunt WA, Craig CR. Alterations in cation levels and Na-K ATPase activity in rat cerebral cortex during the development of cobalt-induced epilepsy. J Neurochem. 1973;20(2):559-567.

49. Rapoport RL Znd, Harris AB, Friel PN, Ojemann GA. Human epileptic brain Na, K ATPase activity and phenytoin concentrations. Arch Neurol. 1975;32(8):549-554.

50. Woodbury DM, Engstrom FL, White HS, Chen CF, Kemp JW, Chow SY. Ionic and acid-base regulation of neurons and glia during seizures. Ann Neurol. 1984;16(1):513-514.

51. Anderson WR, Franck JE, Stahl WL, Maki AA. Na,K-ATPase is decreased in hippocampus of kainate-lesioned rats. Epilepsy Res. 1994;17(3):221-231.

52. Indelis K, Balabin M, Mazzoccarotti MG, CAVLAR C. Human Na+,K+ ATPase activity in the hippocampus of rats subjected to pilocarpine- and ethanol-induced temporal lobe epilepsy. Epilepsia. 2012;53(8):1286-1294.

53. Guillaume D, Grisar T, Delgado-Escueta AV, Bureau-Heeren M, Laschet J. Phosphorylation of brain Na(+)+K(+) -ATPase alpha catalytic subunits in normal and epileptic cerebral cortex: I. The audiogenic mice and the cat with a freeze lesion. J Neurosci Res. 1992;33(1):207-217.

54. Palavoor ST, Sefried TN. Brain cationic ATPase activities in epileptic (El) mice. Exp Neurol. 1988;99(3):768-771.

55. Delgado-Escueta AV, Horan MP. Brain synaptosomes in epilepsy: organization of ionic channels and the Na+-K+ pump. Adv Neurol. 1980;27:85-126.

56. Zaatreh MM, Spencer DD, Thompson JL, et al. Frontal lobe tumoral epilepsy: clinical, neurophysiological features and predictors of surgical outcome. Epilepsia. 2002;43(7):727-733.

57. Reime Kinjo E, Arida RM, Mara de Oliveira D, da Silva Fernandes MJ. The Na+/K+ ATPase activity is increased in the hippocampus after multiple status epilepticus induced by pilocarpine in developing rats. Brain Res. 2007;1138:203-207.

58. Lingrel JB, Kuntzweiler T. Na+,K(+)-ATPase. J Biol Chem. 1994;269(31):19659-19662.

59. Zandt BJ, Stigen T, Ten Haken B, Netoff T, van Putten MJ. Single neuron dynamics during experimentally induced anoxic depolarization. J Neurophysiol. 2013;110(7):1469-1475.

60. Rondouin G, Baldy-Moulinier M, Passouant P. Effect on paradoxal sleep of experimental limbic epilepsy induced by intraseptal injection of ouabain. C R Seances Soc Biol Fil. 1976;170(4):809-814.

61. Petsche H, Rappelsberger P, Frey S, Zuchatzki BU. The epileptogenic effect of ouabain (g-strophanthin). Its action on the EEG and cortical morphology. Epilepsia. 1973;14(2):243-260.

62. Matsumoto S, Kitagawa J, Takeda M. The effects of ouabain on resting membrane potential and hyperpolarization-activated current in neonatal rat nodose ganglion neurons. Neurosci Lett. 2008;439(3):241-244.

63. Fabricius M, Fuhr S, Bhatia R, et al. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain. 2006;129(3):778-790.

64. Freitas ML, Oliveira CV, Mello FK, et al. Na(+), K(+)-ATPase activating antibody displays in vitro and in vivo beneficial effects in the Pilocarpine model of epilepsy. Neurosciences. 2018;37:98-104.

65. Wójtowicz AM, Dvorzhak A, Semtner M, Grantyn R. Reduced tonic inhibition in striatal output neurons from Huntington mice due to loss of astrocytic GABA release through GAT-3. Front. Neurocircuits. 2013:7:188.

66. Roux MJ, Supplisson S. Neuronal and glial glycine transporters have different stoichiometries. Neuron. 2000;25(2):373-383.

67. Wang F, Smith NA, Xu Q, et al. Astrocytes modulate neural network activity by Ca(2+)-dependent uptake of extracellular K+. Sci Signal. 2012;5(218):ra26.

68. Albrecht Z, Zileinška M. Mechanisms of excessive extracellular glutamate accumulation in temporal lobe epilepsy. Neurochem Res. 2017;42(6):1724-1734.

69. Burnstock G. Purinergic nerves. Pharmacol Rev. 1972;24(3):509-581.

70. Khakh BS. Molecular physiology of P2X receptors and ATP signaling at synapses. Nat Rev Neurosci. 2001;2(3):165-174.

71. Dona F, Conceição RM, Ulrich H, et al. Variations of ATP and its metabolites in the hippocampus of rats subjected to pilocarpine-induced temporal lobe epilepsy. Purinerg Signal. 2016;12(2):295-302.

72. Lietsche J, Imran I, Klein J. Extracellular levels of ATP and acetylcholine during lithium-pilocarpine induced status epilepticus in rats. Neurosci Lett. 2016;611:69-73.

73. Engel T, Alves M, Sheedy C, Hensch JL. ATPergic signalling during seizures and epilepsy. Neuropharmacology. 2016;104:140-153.

74. Jimenez-Pacheco A, Mesuret G, Sanz-Rodriguez A, et al. Increased neocortical expression of the P2X7 receptor after status epilepticus in the El mouse. Exp Neurol. 2017:234:493-502.

75. Engel T, Gomez-Villafuertes R, Tanaka K, et al. Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. FASEB J. 2012;26(4):1616-1628.
76. Sperlágh B, Köfalvi A, Deuchars J, et al. Involvement of P2X7 receptors in the regulation of neurotransmitter release in the rat hippocampus. *J Neurochem*. 2002;81(6):1196-1211.

77. Fernández ÁF, Liu Y, Ginet V, et al. Interaction between the autophagy protein Beclin 1 and Na+,K+-ATPase during starvation, exercise, and ischemia. *JCI Insight*. 2020;5(1):e133282.

78. Zhu M, Cao L, Xiong S, Sun H, Wu Z, Bian JS. Na(+)/K(+)-ATPase-dependent autophagy protects brain against ischemic injury. *Signal Transduct Target Ther*. 2020;5(1):55.

79. Condon KJ, Sabatini DM. Nutrient regulation of mTORC1 at a glance. *J Cell Sci*. 2019;132(21):jcs222570.

80. McMahon J, Huang X, Yang J, et al. Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis. *J Neurosci*. 2012;32(45):15704-15714.

81. Yasin SA, Ali AM, Tata M, et al. mTOR-dependent abnormalities in autophagy characterize human malformations of cortical development: evidence from focal cortical dysplasia and tuberous sclerosis. *Acta Neuropathol*. 2013;126(2):207-218.

82. Wilbur C, Buerki SE, Guella I, et al. An infant with epilepsy and recurrent hemiplegia due to compound heterozygous variants in ATP1A2. *Pediatr Neurol*. 2017;75:87-90.

83. Toldo I, Cecchin D, Sartori S, et al. Multimodal neuroimaging in a child with sporadic hemiplegic migraine: a contribution to understanding pathogenesis. *Cephalalgia*. 2011;31(6):751-756.

84. Spadaro M, Ursu S, Lehmann-Horn F, et al. A G301R Na+/K+ -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs. *Neurogenetics*. 2004;5(3):177-185.

85. Riant F, Ducros A, Ploton C, Barbance C, Depienne C, Tournier-Lasserve E. De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine. *Neurology*. 2010;75(11):967-972.

86. Swoboda KJ, Kanavakis E, Xaidara A, et al. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. *Ann Neurol*. 2004;55(6):884-887.

87. Cordani R, Stagnaro M, Pisciotta L, et al. Alternating hemiplegia of childhood: genotype-phenotype correlations in a cohort of 39 Italian patients. *Front Neurol*. 2021;12:658451.

88. Gasser M, Boonsimma P, Netbaramee W, et al. ATP1A3-related epilepsy: report of seven cases and literature-based analysis of treatment response. *J Clin Neurosci*. 2020;72:31-38.

89. Rapport RL 2nd, Ojemann GA. Prophylactically administered phenytoin. Effects on the development of chronic cobalt-induced epilepsy in the cat. *Arch Neurol*. 1975;32(8):539-548.

90. Funck VR, Ribeiro LR, Pereira LM, et al. Long-term decrease in Na+,K+-ATPase activity after pilocarpine-induced status epilepticus is associated with nitration of its alpha subunit. *Epilepsy Res*. 2014;108(10):1705-1710.

How to cite this article: Sun J, Zheng Y, Chen Z, Wang Y. The role of Na+ - K+ -ATPase in the epileptic brain. *CNS Neurosci Ther*. 2022;28:1294-1302. doi: 10.1111/cns.13893